ARQT vs UTHR
Arcutis Biotherapeutics, Inc. vs United Therapeutics — AI-powered side-by-side comparison
ARQT
Arcutis Biotherapeutics, Inc.
64
Buy
VS
UTHR
United Therapeutics
72
Buy
| Metric | ARQT | UTHR |
|---|
| AI Score |
64
|
72
|
| Price |
$26.21
|
$514.89
|
| P/E Ratio |
118.80×
|
17.05×
|
| ROE |
-8.5%
|
18.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
91.1%
|
86.1%
|
| Debt / Equity |
0.52×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
44.7
|
52.2
|
| Beta |
1.526
|
0.564
|
| Expected Upside |
—
|
+6.4%
|
AI Committee View
Current Innellis committee reasoning for ARQT versus UTHR.
UTHR leads by 8 points.
UTHR scores 72/100 (Buy) versus ARQT at 64/100 (Buy).
ARQT Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
UTHR Committee View
80% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Lower Highs / Lower Lows structure confirms bearish price action.
- Risk/reward is unfavorable: 13.5% downside vs 6.4% upside.